This presentation reviews the male reproductive system, concentrating on newer advances in our knowledge of its physiology, biochemistry, and regulation, and introduces the topic of male reproductive toxicology.
INTRODUCTION
The purpose of this review is to discuss the latest developments in the physiology and endocrinology of the male reproductive, system and to use this overview to introduce the topic of reproductive tox-, . icology. It should be emphasized that many of the advances in our understanding of the reproductive system come from the general field of endocrinology. Therefore, we will first describe some of the major advances in endocrinology and then show how they have played a major role in increasing our understanding of the reproductive system. Our discussion will necessarily be limited in scope, choosing only a few of the numerous exciting developments in endocrinology for discussion; and several of these will not be discussed in as much detail as is known. Our focus is the new and exciting areas, not all the 412 HEINDEL AND TREINEN TOXICOLOGIC PATHOLOGY to specific receptors, and the steroid-receptor complex then binds to specific acceptor sites on the nuclear matrix. Activation of the nuclear acceptor sites results in the initiation of transcription and the production of new mRNA (48). The mRNA is translated in the cytoplasm to produce new protein. All steroids, therefore, act by stimulating the production of proteins. These new proteins then modify cell function. This is a relatively slow process; steroids require several hours to alter cell function. Note that thyroid hormones, while not having a steroid structure, act via a mechanism similar to steroids in that they bind to receptors which couple to nuclear acceptor sites which stimulate RNA-dependent protein synthesis. "Peptide Hormones. " For the purposes of this discussion, all non-steroid, non-thyroid hormones will be placed in the category of "peptide hormones." This includes amino acid derivatives, prostaglandins, peptides, proteins, and glycoproteins. These molecules share a similar characteristic in that they cannot pass through the lipid portion of the cell membrane ( Fig. 1 ). In order to be able to carry out their role as metabolic regulators, they must bind to specific receptor molecules on the cell membrane and thereby transmit a message to the interior of the cell. As shown in Fig. 2 , there are 2 types of receptor systems which these "peptide" hoimones utilize. System No. 2 is the classic second messenger system of which the cAMP system is the prototype. We now know that the regulation of ion channels and the calcium/inositol trisphosphate second messenger systems also utilize this system (22, 74, 154). This system has 3 components: a receptor which is specific for a particular hormone, a transducer molecule which recognizes an activated receptor (i.e., hormone-receptor complex), and an effector molecule. When the hormone binds to the receptor on the cell surface, this hormone-receptor complex is able to couple to and activate the transducer. The transducer, when activated, performs 2 tasks: it causes the hormone-receptor complex to dissociate (thereby allowing the process to start again) and at the same time couples to and activates the effector. This is a self limiting process which is extremely short-lived and apparently results in the transducer and the effector returning to their original state ready to be stimulated again. The effector faces the inside of the cell (or may be an integral protein which passes through the entire membrane), and when activated, increases the concentration of the second messenger. The effector can be an enzyme which, when activated, synthesizes the second messenger or part of an ion channel which when activated opens or closes the channel, altering the concentration of a second messenger. This receptor- transducer-effector system will be described in more detail in the sections on cAMP and calcium.
System No. 1 is the more recently discovered of the 2. It consists of a receptor which itself is also the effector. Thus, there is no need for a transducer (39). Binding of a hormone to the receptor activates the effector portion of.the receptor directly.
mones" into two types of receptor-messenger systems. In the Type 1 mechanism, the hormone receptor is the effector. In the Type 2 mechanism, a transducer couples the receptor to the effector. in the cell, which is a regulatory subunit of an inactive protein kinase. When cAMP binds, the regulatory subunit dissociates from the protein kinase. This protein kinase is thereby activated and it covalently modifies specific cellular proteins by phosphorylating serine or threonine residues. Phosphorylation alters the activity of these proteins, some of which are enzymes, while others may be structural proteins (there are examples of phosphorylation causing both activation or inactivation of proteins). A phosphatase is needed to remove the phosphate from these proteins and return their activity to the basal state.
It should also be noted that the intracellular level of CAMP is controlled by 2 enzymes: adenylate cyclase which stimulates its production and a phosphodiesterase which breaks down the cAMP to adenosine monophosphate (AMP). Under basal conditions the phosphodiesterase is able to keep the cAMP level low enough so that the CAMP-dependent protein kinase is relatively inactive. Upon stimulation of adenylate cyclase by hormones, the concentration of cAMP can increase sufficiently to activate the protein kinase because synthesis of cAMP proceeds faster than degradation by phosphodiesterase. Once the stimulatory signal is stopped, the levels ofcAMP fall to basal levels which are too low to activate the protein kinase. Note, however, that it takes more than the lowering of cAMP levels to shut this system down. The phosphate must be removed from the serine or threonine residues of the phosphorylated proteins. This process, too, is probably regulated, but its control is currently unclear.
Examination of Fig. 3 shows that there is another RECEPTORS TRANSDUCERS CAMP FIG. 3. -Schematic of the cAMP second messenger system. This is a Type 2 system in which the hormone receptor complex activates a transducer which, in turn, activates the effector. In this case, the effector is the enzyme adenylate cyclase which, when activated, converts ATP to cAMP and pyrophosphate. The enzyme(s), (there are both soluble and membrane bound enzymes), phosphodiesterase, converts the cAMP to the inactive AMP, which can be reconverted to ATP. Note that there are both stimulatory (N,) and inhibitory (NJ transducers and hence stimulatory and inhibitory pathways, which result in fine tuning control of the system. aspect of this system: both stimulatory and inhibitory pathways exist (93, 106) . Some hormones bind to specific receptors which couple to the stimulatory transducer (Ns), thereby activating adenylate cyclase, and others bind to receptors which couple to a similar transducer (Ni) which, when activated, prevents or inhibits the activation of adenylate cyclase. This dual control system results in "fine tuning" of the intracellular levels of CAMP. The ultimate level, and thereby the extent of stimulation of the protein kinase, will depend on the interplay of the stimulatory and inhibitory hormones present. This is obviously an important control mechanism which is just beginning to be appreciated.
We will now examine this system at a more biochemical level in order to understand how it functions ( Fig. 4) . Details can also be found in the following reviews: 21, 22, 93, 254. The transducers noted as Ns or Gs (depending on the author) for stimulatory and Ni or Gi for inhibitoj are each composed of 3 subunits: a, p, and y. The 8-y complex is similar for both Ns and Ni, while the a subunits differ slightly in molecular weight. While our understanding of these transducers is still incomplete, it appears that the a subunits are the only ones with enzymatic activity. There is a GTPase asso-. ciated with the CY subunits which converts GTP to a GDP and inorganic phosphate. The activity of this enzyme is very low compared to most other enzymes and is the key to understanding the activity of the transducers at a molecular level.
In the basal state, the receptor, transducer, and catalytic units are separate moieties in the cell mem- ' at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from . TOXICOLOGIC PATHOLOGY brane (Fig. 4) . The basal state of the transducer is the trimer a#Iy with GDP bound at the active site of the GTPase. When the hormone binds to the receptor, the hormone-receptor complex is activated (presumably an active site is uncovered by a conformational change produced by hormone binding) so that it can interact with the transducer. The hormone-receptor complex, upon binding to the transducer, releases the GDP from the transducer and allows GTP to bind. GTP binding causes the transducer to dissociate into 2 parts. The dissociation of the transducer into an a-GTP and By subunit also releases the hormone-receptor complex and results in dissociation of the hormone from the re-. ceptor. The a-GTP transducer subunit binds to the adenylate cyclase catalytic unit resulting in its activation, and a burst of cAMP is produced. Since the a-GTP transducer subunit has GTPase activity within a "split second" of activation, the GTPase converts the bound GTP to GDP. This results in dissociation of the transducer a subunit from the adenylate cyclase (which therefore reverts to an inactive state) and the reassociation of the a-GDPDy subunits to the inactive transducer. At this point, the whole system is back to the "basal" state awaiting hormone binding to receptor in order to initiate another cycle. A similar phenomenon occurs when a hormone binds to the inhibitory transducer. Thus, the transducer (Ni), when activated, dissociates into an ai-GTP and #IT subunit. The exact mechanism whereby this transducer inhibits the activation by a stimulatory hormone is not resolved. Notice that there are 2 possibilities. The q-GTP transducer subunit could bind to the adenylate cyclase and somehow alter its conformation so that the a,-GTP (stimulatory transducer) is not able to activate the cyclase. Alternatively, the By subunits (remember that the #Iy subunits of Ns and Ni are the same) could, by virtue of the law of mass action and their high concentration, combine with the a,-GTP/a,-GDP, thereby lowering their concentration and then, therefore, their ability to activate the adenylate cyclase. At present, there is evidence for both theories, but the former seems to have greater support.
Much of the interest in this system at present concerns the isolation and purification of the components and the determination of the exact role of the a and By transducer subunits in the activation of the system. .
Calcitiin Second Messenger Systenz.. The cellular actions of many "hormones" (i.e., endocrine, paracrine or autocrine regulators), neurotransmitters, and drugs are mediated by an increase in intracellular Ca2+. An increase in cytosolic calcium can result from either an increase in flux through cell membrane Ca2+ channels or release from intracellular stored pools. In fact, these 2 processes seem to be independently regulated and therefore will 6e considered separately.
Iigiu: of Extracellular Calciiiin. Virtually all eukaryotic cells have alarge (1 0,000-fold) calcium gradient across their cell membranes. The level of Ca2+ outside the cell is around I mM and the concentration inside a resting cell is 0.1 p~. This gradient allows for alterations in intracellular Ca2+ levels. A rise in intracellular-free Ca2+ ions can easily be achieved by a momentary increase in the permeability ofthe cell membrane to calcium. Indeed, this can be accomplished by the opening of either voltage-regulated or receptor-operated calcium channels in the cell membrane. While only excitable cells possess voltage-regulated Ca2+ channels, most cells have receptor-operated channels (4, 262) . It is the operation of these receptor-operated channels that we will consider further. The receptor-operated channels fit the Type 2 receptor systems discussed previously. They consist of a receptor which recognizes the "hormone," a GTP binding transducer, and the effector; in this instance the effector protein controls access to the calcium channel ( Fig. 5) . The process of hormone binding to receptor, activation ofthe transducer, etc., detailed for the cAMP system appears to be similar for the activation of this calcium channel, although all the details have not been clarified.
Once the levels of intracellular calcium increase to the micromolar range, Ca2+ binds to specific intracellular receptors generally referred to as calcium binding proteins (63, 108, 128, 262) . These intra-. cellular calcium binding proteins are thereby activated and interact with their target protein($ to regulate their enzymatic or biological activities. Thus, all of the known biological actions of Ca2+ are due to its interaction with these specialized calcium EXCHANGE Na Jct + GTP
W"
FIG. 5.-General schematic of the calcium second messenger system. Calcium can enter the cell via receptor operated channels (1) or via release from intracellular pools (2) . Intracellular calcium can be lowered by extrusion from the cell via the Ca2+ ATPase or the Nat/Ca2+ exchange or by reuptake into the intracellular storage pools. binding proteins. The 2 most prominent calcium binding proteins in cells are troponin C found in skeletal muscle cells and calmodulin, which is a universal calcium binding protein present in all eukaryotic cells (63, 108). The Ca2+-calmodulin complex has been shown to regulate the activity of more than 30 proteins. These proteins in turn modulate various biological processes which have been ascribed to calcium, i.e., neurosecretion, microtubule formation, cell differentiation, granule secretion, and DNA replication, to name a few.
Ofcourse, an ideal second messenger system must not only have a mechanism for raising the second messenger concentration, but it must also be able to quickly and efficiently lower the second messenger levels once the stimulation has ceased,.so that cellular processes may return to a basal state. Indeed, the Ca2+ second messenger system has several, mechanisms for quickly lowering cytosolic Caz+ ' levels ( Fig. 5) . First, the receptor-operated Ca2+ channels are feedback regulated; when the intracellular Ca2+ reaches a specific level, the channel is closed. Second, the cell contains Ca2+-ATPases and Na+-Ca2+ exchange systems which function as selective calcium pumps secreting Ca2+ into either the extracellular space or into intracellular storage organelles (endoplasmid reticulum or mitochondria) (4). It appears that the mitochondria serve as a secondary intracellular calcium sink where Ca2+ is stored as a hydroxyappetite precipitate in the matrix (37).
Release of Intracellirlar Calciim (Calcium-Phosphoirrositide Systertz).
It is now clear that intracellular levels of Ca2+ can be stimulated (with subsequent activation of calcium-dependent processes) not only by voltage and receptor-activated channels in the cell membrane, but also by release of stored pools of intracellular Ca2+ (even in the absence of Endoplumlc ReUculum FIG. 6 .-Schernatic of the Ca*+/IP, second messenger system. Hormone binding to the receptor couples through the transducer to activate the effector system (phospholipase C). Phospholipase C acts on membrane phosphorylated phosphatidylinositol to yield two second messengers; IP, and diacylglycerol. IP, releases Ca2+ 'from intracellular stores and diacylglycerol activates protein kinase C (C-kinase) which phosphorylates proteins. extracellular calcium). The mechanism whereby a cell membrane-rnediated event (i.e., hormone binding to receptor) could result in the release of intracellular stores of calcium has only recently been delineated. The increase in free intracellular Ca2+ released from. intracellular stores has now been associated with an increase in membrane phospholipid turnover (specifically, phosphatidylinositol). We will therefore review the recent developments in the biochemistry of phospholipid turnover and then show how this is related to activation of the calcium second messenger system (1, 18, 109, 213, 230) .
Phosphatidylinositol is a component of all eukaryotic cell membranes. It is unique in that it can be further phosphorylated via ATP-dependent kinases to give phosphatidylinositol4-phosphate and phosphatidylinositol4,S-bisphosphate. Hoken and Hoken (reviewed in 1, 230) were the first to show that there was a link between the incorporation of 32Pi into membrane phosphoinositides and hormonal stimulation of a cell. In 1975, Michell (174) reported a correlation between phosphate incorporation into membrane phosphatidylinositol and the . Ca2+ mobilizing action of certain agonists. This was followed by the realization that breakdown of the polyphosphorylated inositols correlated with the Ca2+ response (1) and finally to the identification of inositol 1,4,5-trisphosphate (IP3 or inositol trisphosphate) as the water soluble product of the breakdown of polyphosphorylated inositol and the hypothesis that this water soluble product might be . . at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from a second messenger (18, 19) . The enzyme which catalyzes the breakdown of polyphosphoinositol to IP, and diacylglycerol has been identified as phospholipase C (109). More recently, the diacylglycerol product has also been shown to be a second messenger; it activates a specific protein kinase termed protein kinase C (C-kinase) (109). A simplified schematic of this Ca2+-inositol trisphosphate second messenger system is shown in Fig. 6 . Essentially, the system works as follows. A small portion (10-20%) of the plasma membrane pool of phosphatidylinositol is in the form of poly-phosphatidylinositols. Phosphatidylinositol 4,5-bisphosphate is the substrate for phospholipase C. The system is activated by a hormone binding to a specific membrane-bound receptor which is coupled to phospholipase C via a GTP binding transducer. The hormone-receptor-transducer-effector system is of the Type 2 variety, and its activation process is similar to that of the cAMP system (187) . Upon activation (see Fig. 7 ), phospholipase C cleaves the phosphatidylinositol 4,5-bisphosphate to yield IP, (inositol 1,4,5 PO4; inositol trisphosphate), and diacylglycerol. The water soluble IP, is released into the cytosol where it then binds to a specific receptor on the endoplasmic reticulum which may be connected to, or an integral portion of, a calcium channel. This results in a release of Ca2+ from the endoplasmic reticulum stores into the cytosol. The increased cytosolic Ca2+ then binds to calmodulin as described previously. The Ca2+-calmodulin complex is the active component which modulates numerous cellular functions. Recently, other water soluble phosphoinositide metabolites (inositol I ,3,4,5 PO, and inositol1,3,4 PO,) have become candidates for second messengers, although their role is not clear at the present time (18) . It should be noted that the IP, receptor may not actually be on the. endoplasmic reticulum, as there is recent evidence that the IP, target may be discreet organelles distributed throughout the. cytoplasm called calciosomes (291) . IP, is short-lived and is degraded to the inactive metabolites IP, and IP and inositol by specific phosphomonoesterases.
Diacylglycerol (DAG), the lipid product of phosphoinositide cleavage by phospholipase C, remains in the membrane and is now also considered to be a second messenger. DAG appears to be the physiological activator of a ubiquitous cytosolic protein kinase designated protein kinase C (C-kinase). Brain C-kinase is a monomer of 80,000-90,600 daltons which contains a hydrophobic domain which interacts with Ca2+ and phospholipid and a hydrophilic active site.
C-kinase in unstimulated cells can be either cytosolic (inactive) or membrane-bound and com- plexed to phosphatidyl serine and Ca2+ (inactive but primed). DAG, produced when the Ca2+/IP, system is activated, interacts with the membrane-bound primed C-kinase, thereby stimulating its catalytic activity (1 1). DAG is produced only transiently and disappears within a few seconds to minutes. C-kinase will be inactivated as the DAG concentration declines. Note, however, that analogous to the cAMP system, removal of the second messenger does not immediately stop the signal, since the proteins Chosphorylated by the C-kinase will remain phosphorylated and active until the phosphate is removed by phosphatases. Thus, a transient signal can give rise to a more long-lasting response (4) . While the cellular substrates for C-kinase have not been defined, it seems that membrane-associated proteins are a prime target for phosphorylation. A specific system which is activated by C-kinase is the Na+/H+ exchange transport system which increases cytoplasmic pH. This may be important in cell proliferation since an increase in pH is characteristic of the action of growth factors and tumor promoters (192) .
The relationship between the activated products of these 2 systems (Ca2+/IP, and DAG/C-kinase) is not clear. In many cells, the 2 pathways appear to act synergistically by stimulating different cellular responses needed for the full physiological response. In platelets, for example, thrombin, which activates the Ca*+/IP,-DAG/C-kinase second messenger systems, stimulates the phosphorylation of 2 proteins with molecular weights of 40K and 20K. DAG specifically results in the phosphorylation-of the 40K protein, while addition of a calcium ionophore results in the phosphorylation of the 20K protein.
Phosphorylation of both proteins is needed for the full physiological response (serotonin release) to occur (109). In other cells, it appears that the IP, release of Ca2+ is the primary signal, and the DAG/ C-kinase pathway acts as a modulator of either the Cat+ signal or other signaling pathways (1 8, 230) .
With respect to its similarity to the cAMP second .
messenger system, one might ask whether there is an inhibitory 'pathway as part of this Ca2+/DAG system. Indeed, there is intense interest in this area, and Bell et a1 (1 1) have proposed that sphingosines (another class of membrane lipids) may activate a putative inhibitory pathway.
An incomplete list of receptors which act via the Ca2+/IP3 system (1, 77) include: adrenergic (a,), muscarinic (M,), histamine (HI), thrombin, angiotensin 11, dopamine (DJ, platelet-derived growth factor, GnRH, fibroblast growth factor, lectins (concanavalin A), and luteinizing hormone.
In addition to short-term alteration of cellular metabolism, activation of this Ca2+/IP3 dual pathway system appears to be important in cell proliferation. Several growth factors activate this second messenger system (i.e., platelet-derived growth factors, fibroblast growth factors, and leukotrienes) (42).
A second line of evidence comes from the study of tumor promoters. Tumor promoters are chemicals which are not carcinogenic by themselves but increase the probability of an "initiated" cell becoming malignant (42). The' tumor promoter phorbol. esters (i.e., phorbol-l2-myristate-l3-acetate (PMA),' and 12-o-tetradecanoylphorbol-13-acetate (TPA), aplysiatoxin, teleocidin B, and lyngbyatoxin A) all act by activating C-kinase (42). Indeed, C-kinase is the major phorbol ester receptor (26). Phorbol ester binding to the cell membrane results in the translocation of the cytosolic C-kinase to the cell membrane and its activation. Notice that phorbol esters bypass phospholipase C activation so. that the activation of C-kinase occurs in the absence of a rise in intracellular Ca2+. The discovery of C-kinase as the receptor for tumor promoters has not only increased interest in the importance of the Ca2+/IP,-DAG/C-kinase pathway to cancer, but also has given scientists a tool to dissect this pathway into its component parts in the hopes of determining both their separate roles and their interaction. Another line of evidence comes from the study of oncogenes. The protein encoded by the normal cellular counterpart of the ras oncogene may be a component of the Ca2+/IP3 messenger system. Indeed, it appears that the ras gene encodes for a GTP binding transducer protein (22) . The ras product apparently stimulates' phospholipase C without receptor activation, thereby causing the cells to behave as if they are undergoing stimulation when they are not. Other oncogene products which are related to the Ca2+/IP, system include sis, fos, and inyc (255) .
Interaction between the cAMP and Caz+/IP3 Secondhfesseriger Systerns.
Most, ifnot all, eukaryotic cells possess both the cAMP and Ca2+/IP3 second messenger systems. There are now numerous reports on the possible interactions between these 2 systems. A detailed analysis of these reports is beyond the scope of this review. However, a few points can be made. First, there are "hormones" which activate both systems. When they do, each system appears to be activated via a separate specific receptor. For example ( Fig. 8 ) catecholamines act through either LY or @ receptors. Beta receptors @l or 82) are coupled via the production of CAMP. However, a receptors.are divided in their coupling to second messengers. Alpha, receptors activate the inhibitory cAMP pathway while aI receptors couple to the Ca2+/IP3 system (77, 94) .
Secondly, there are multiple points of interaction between the 2 systems, a summary of which has been presented by Nishizuka (1 92) and is shown in Fig. 9 . In bi-directional systems, the 2 second messengers counteract each other, while in the monodirectional system, one class of receptors may potentiate the other one. A basic understanding of these possible interactions helps one to understand the results when 2 hormones acting through different systems act on the same cell (which is usually the case in vivo).
Since phosphorylation via protein kinases plays such an important role in the activity ofthese second messenger systems, I important mechanism whereby interaction could occur would be through phosphorylation of 1 or more of the structural components of the second messenger systems. In this regard, it is known that phosphorylation of receptors in some cases leads to desensitization or uncoupling of the system (1 15, 239, 240) .
Receptors. In a previous section, we described Types 1 and 2 second messenger systems. While the. data are still limited, it now appears that the hormone receptors which couple to each type of second messenger system belong to specific families. Three specific receptors, which couple to the Type 2 system (receptor-transducer-effector), have been purified, cloned, and sequenced. As shown in Fig. 10 , these receptors are the @ adrenergic receptors from 3 species (human, hamster, and turkey) which couple to the cAMP system; the muscarinic receptor (porcine cerebral; M1) which couples to the Ca2+/IP, system; the muscarinic receptor (cardiac; M2) which couples through the cAMP system; and rhodopsin (66, 132) : Rhodopsin is representative of a class of visual pigments which also couple through GTP binding transducers. Notice the striking similarity of these receptors; all are integral membrane proteins with 7 membrane-spanning regions, all are glycoproteins (carbohydrates on extracellular regions only), all have a long (but variable) cytoplasmic region in addition to 3 cytoplasmic Ioops, and all have specific phosphorylation sites on cytoplasmic regions. There is clear evidence that phosphorylation of the receptor is common to most, if not all, receptors and that it constitutes a regulatory mechanism which reduces their ability to interact with the transducer (Lei, desensitization). See references 1 1'5 and 240 for reviews on the physiological importance of membrane receptor phosphorylation. It has been proposed that the interaction between the receptor and transducer occurs through the cytoplasmic loops which are highly conserved among the receptors. The similarities in these receptor structures suggests that they may have come from gene duplication events on some common ancestral gene, and they lead one to hypothesize that all receptors which couple to effector systems through GTP binding transducers may have a similar structure (66) .
Bidirectional control symtems
In contrast to receptors that couple to GTP-binding transducers, receptors for a variety of growth factors including epidermal growth factor, plateletderived growth factor, insulin, and insulin-like growth factor I (somatomedin C) are themselves effectors. These Type. 1 receptors are all proteintyrosine kinases. The structure of these receptors are both noticeably different from the Typ; 2 receptors and noticeably similar to each other ( Fig.  11 ). Once again, these receptors are similar enough to suggest that they may have evolved from a common ancestral gene. They are all glycoproteins with a single membrane-spanning region per subunit, all have protein-tyrosine kinase activity associated with the cytoplasmic domain and they all have the ability to be phosphorylated (for reviews see 39, 90, 193, 240) . The hormones which couple to this type of receptor have not yet been shown to produce a second messenger. They all appear to act by activating . a receptor tyrosine-protein kinase which phosphorylates tyrosine residues on cellular proteins, thereby altering their activity. The activation of tyrosine kinase has been specifically associated with the stimulation of cell growth rather than differentiated function. It remains to be determined whether other growth regulators will bind to Type 1 receptors.
In summary, we have discussed the mechanism whereby most "hormones" are able to regulate cell function. There is both simplicity and complexity to these mechanisms. Simplicity in that each "hormone" doesn't have its own unique second messenger system. Although there are literally dozens of "hormones," they can be easily categorized into just a few systems. All steroids, in general, fit the same mold; all other "hormones" can be categorized into just a few receptor types (1 and 2) and second messenger systems (CAMP, Ca2+, Ca2+/IP3). Nonetheless, within and between each system there is considerable complexity. The multiple components of the second messenger system allows for a cascade of events with multiple points of amplification, such that a single "hormone" can stimulate the formation of tens of thousands of second messengers. Each part of the system is a possible point of regulation, thus,.
the multiple components allow for a complex, finely' regulated system. Regulation is even more complex in that we now realize that each of these second messenger systems is present in every cell and regulated in that cell by multiple "hormones." Thus, one of the major areas of future research is in trying to understand the impact of the activity of these multiple second messenger systems within a single cell.
Endocrine, Paracrine arid Autocriiie Regulation. In the past decade. or so, the field of endocrinology has been revolutionized by the discovery-of factors which regulate cellular growth and differentiation which do not fall into the specific definition of a hormone. Traditionally, hormones have been characterized as products released from an endocrine gland into the bloodstream, which alter the activity of distant cells. This definition of a classical hor- mone was found to be too strict to encompass the hypothalamic "factors" which were not released into the peripheral bloodstream but into a local circulation, the hypophyseal portal system, and which acted only locally at the level of the hypothalamus. Even today these hypothalamic'releasing factors are sometimes called 'factors' and sometimes 'hormones.' Recently, the problem has been further complicated by the discovery of literally dozens of cellular regulators which are not released into the general circulation. These regulators (generally classified as growth factors), which act "locally'' on neighboring cells, have been called paracrine regulators, while those which act on the cell which produced them are called autocrine regulators. Thus, as shown in Fig. 12 , we now recognize endocrine, paracrine, and autocrine regulation. The classical hormones fit into the category of endocrine regulation. Since a particular agent can be an endocrine, paracrine, and autocrine regulator at the same time (i.e., testosterone), it is easy to see the dilemma faced by endocrinologists. This nomenclature problem is still unresolved. For the purposes of this review, the term "hormone" will be used in the broadest sense to mean any endocrine, paracrine, or autocrine regulator.
Growth Factors. A detailed discussion ofthe over 30 growth factors which have been dkscribed is beyond the scope of this review. Table I lists some of the growth factors which have been characterized. Several reviews detailing the structure and activity of these growth factors are available (31,38,49,64, 150, 187, 263). Examination of the growth factor literature can, however, give us some general information which will be helpful to our understanding of the control of reproductive function.
First, the discovery of growth factors specific for. certain tissues led to the use of the new terminology of paracrine and autocrine regulators. It has been shown that growth factors usually act on neighboring cells via a paracrine action, since normally the cells producing them do not have receptors for the factors they produce. One of the hypotheses of cancer (the autocrine hypothesis) involves the ability of oncogenes to make cells independent of growth factors (255) . Essentially, this hypothesis states that cancer cells produce their own growth factors, i.e., they are regulated in an autocrine fashion and thus are capable of growth without stimulation by paracrine factors. Indeed, several oncogenes have been shown to cause cells to act as if certain growth factors were provided. For example, erb-b is a modified epidermal growth factor receptor which is activated in the absence of epidermal growth factor, so cells possessing this oncogene do not need the growth factor; it is "provided" in an autocrine fashion.
Second, proper regulation of growth involves a complex interaction of endocrine, paracrine, and autocrine regulators. For example, in BALB/c 3T3 cells in culture, 3 specific mitogenic factors are required for growth. Platelet-derived growth factor renders the cells competent, epidermal growth factor (EGF) primes competent cells and then insulin-like growth factor I1 (IGF-11) induces proliferation of competent, primed cells (4).
Third, agents discovered and named for a specific effect aren't necessarily restricted to that effect. In fact, other' subsequently discovered actions may prove to be more pertinent; leaving the agent misnamed. A prime example of this sequence is the transforming growth factors a and / 3 (TGF-a and TGF-p). They were discovered and named because of 'their ability to "transform" normal anchoragedependent fibroblast cells in culture to cells which could grow on soft agar (187) . Indeed, TGF-a is a 6,000-kD peptide which is an epithelial cell mitogen which acts via binding to the EGF receptor (its effects therefore mimic those of EGF) (38, 187). TGF-p, on the other hand, is a 25,000-kD homodimer which, except for its unusual effect on fibroblasts, is devoid of mitogenic activity and is the most potent growth inhibitor known. Most normal cells produce TGF-/I and in addition to its growthinhibiting properties it stimulates cells to produce extracellular matrix. It therefore may play an important role as a normal growth inhibitor in tissues (64, 187):
Fourth, several tissue-specific growth factors may turn out to be the same compound. For example, BSC-1 (a growth inhibitor from the green monkey) and cartilage inducing factor (CAF-A) have been shown to be homologous to TGF-8 (64) . Also, tumor necrosis factor has been shown to be homologous with cachectin and quite similar to lymphotoxin (92j.
Last, the discovery of paracrine and autocrine regulators of growth led to the search for and discovery of numerous paracrine and autocrine regulators of cell function. These compounds do not necessarily control cell growth, but in many cases are involved 
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Stimulators of cell growth Epidermal growth factog (EGF) Fibroblast growth factor (FGF)
Platelet-derived growth factor (PDGF)
Insulin-like growth factor I (somatomedin) (IGF-I) Insulin-like growth factor I1 (IGF-11) Colony stimulating factors Transforming growth factor a (TGF-a) Interleukins
Transforming growth factor @ (TGF-8) Tumor necrosis factor (Cachectins) Interferons Mullenan inhibiting hormone (MIH)
Inhibitors of cell growth
See reviews cited in text for specific references.
in the modulation of differentiated function. In the following sections, we will examine the reproductive system with special emphasis on the newly discovered endocrine, paracrine and autocrine mechanisms involved. It should be noted that our kflowledge of paracrine and autocrine regulation of growth and differentiated function is in its infancy. A lack of information should'not be taken as a lack of paracrine and autocrine control, but a lack ofknowledge regarding these processes.
RECENT ADVANCES IN MALE REPRODUC~IVE PHYSIOLOGY Piilsatile Hormone Release
The male reproductive system is regulated by a complex interaction between the central nervous system, hypothalamus, pituitary and testis (Fig. 13 ). The main controlling center of this complex is the hypothalamus, which synthesizes and releases a decapeptide gonadotropin releasing hormone (GnRH also designated LHRH). GnRH is released in a pulsatile fashion by hypothalamic neuronal terminals adjacent to the hypothalamo-pituitary poital microcirculation. For review of GnRH synthesis, location, control of release and overview of feedback control of the reproductive system see references 82, 190 ,24 1, and 294.
The stimulus for this pulsatile release of GnRH in the monkey has been localized to the arcuate region of the mediobasal hypothalamus which has been designated as the "hypothalamic pulse-generator." In the basal state, a bolus of GnRH is released into the portal system approximately every hour in monkeys and humans (1 39). The exact site of these pacemaker cells in the hypothalamus has not been identified. However, the release of GnRH . has been correlated with increased electrical activity (multiunit electrical activity) in the arcuate nucleus. It is also clear that the frequency ofthe GnRH pulses is modulated by CNS influences on the pulse gen- This loss of response to continued exposure has been used recently in clinical situations. Continuous perfusion with long-lasting GnRH analogues has been evaluated for potential use as an antifertility regimen, while administration of pulsatile GnRH can restore fertility when the infertility is of hypothalamic origin (56) .
GnRH acts on the pituitary via specific receptors which couple to the Ca2+-IP, system (50) (described in detail in previous section; the result of this interaction is an increased synthesis of LH in the pituitary and pulsatile release of LH into the general circulation. The frequency of LH pulses is therefore directly related to the frequency of GnRH release. However, the amplitude of LH pulses depends not only on the amount and frequency of GnRH, but also on the "sensitivity" of the pituitary gonadotrophs to the GnRH. For example, testosterone is a feedback regulator of LH, and one of its major effects is on the pituitary where, by an unknown mechanism, it reduces the pituitary response to the GnRH pulse. It should be noted that in addition to the pulses of LH (and other hormones) there is also basal secretion of hormones. This low level of secretion may prepare and prime a tissue, such as the anterior pituitary gland, to respond more effectively to the superimposed pulses.
In addition to LH, GnRH also stimulates FSH (follicle stimulating hormone) release. However, the serum concentration of FSH is low and the half-life is long compared to that of LH; both of which tend to dampen the pulsatile response. Nonetheless, it is clear that FSH is stimulated in discrete pulses with a frequency similar to that of LH (190) .
LH and FSH are the main trophic hormones of the testes. They act on the testes to produce testosterone (endocrine product) and spermatozoa (exocrine product). In the next sections, we will discuss new developments in the regulation of the production of these 2 products of the testis. Emphasis will be on the paracrine and autocrine regulation of the action of LH and FSH which results in a highly and precisely regulated system.
Spermatogenesis
Spermatogenesis, the process of generation of the male gamete, can be divided into 4 distinct phases: development and mitosis of the undifferentiated spermatogonia, spermatocyte development via meiosis, spermiogenesis (differentiation of spermatids), and spermiation (release of spermatid). (For recent reviews see 146,202,205,273, and 293.) This general process has been extensively studied and it will just be overviewed here to set the stage for newer developments.
Spermatogenesis takes place in the seminiferous tubules of the testis in association with the Sertoli cells. The most undifferentiated spermatogonia (stem cells) reside atop the peritubular cell layer at the periphery of the tubule. These undifferentiated spermatogonia reside outside the blood-tubule barrier, which is formed by tight junctions between adjacent Sertoli cells. The spermatogonia divide mitotically to yield either stem cells (type A "dark" spermatogonia), or cells committed to differentiation (type A "pale" spermatogonia). The committed spermatogonia then undergo mitotic divisions through intermediate and type B spermatogonia to become preleptotene spermatocytes which "pass through" the blood-testis barrier. Once luminal to this barrier, they continue the long meiotic prophase (zygotene, pachytene, diplotene) protected from the immune system. This is important because during this development, they express surface proteins that the immune system classifies as foreign, or "non-self." Pachytene is the longest step during which there is extensive recombination of the paired chromosomes. A short-lived diplotene spermatocyte then divides to yield 2 secondary spermatocytes, which quickly enter the second meiotic division to produce the haploid spermatid. During the third phase, spermiogenesis, the spermatids differentiate into the familiar spermatozoa. During spermiation, the excess cytoplasm is stripped from the spermatozoa to form a residual body which is phagocytosed by Sertoli cells and the sperm are released into the tubular lumen. Once initiated at puberty, the process of spermatogenesis is continuous. This process is reinitiated approximately every 13 days in the rat and the time for a spermatogonium to become a mature spermatid is approximately 50-60 days in the rat (Fig. 15 ) (34.5 days mouse, 35 days hamster, 48 days rabbit, and 70 days man).
Because a new cycle starts every 13. days, and it takes 4% cycles (50-60 days) to traverse the entire process, specific cell associations are generated (Fig.  16 ). In the rat, 14 specific cell associations also called stages have been identified (Fig. 17) . That is, if one cuts the tubules in cross section and puts the matching cross sections into piles, there would be 14 piles in aiding our understanding of the effect of toxicants on the spermatogenic processes. Since we know what cell associations should be present in each stage of spermatogenesis, tubules with missing cell types or cells in the wrong stage would indicate an altered spermatogenesis. For example, mature spermatozoa are normally released in Stage VIII. If they are still present in what appears by examination of the other cell types to be a Stage IX tubule, then it is evident that something has disrupted spermiation. Also, one can qualitatively determine if all the stages are present or quantitatively count each cell type in each stage to examine for effects of toxicants.
Transillumination of the Seitiiiiijieroiis Epitheliiiin. As described above, there is a wave of spermatogenesis along the seminiferous tubule. Parvinen reported in the early 1970s that when a living unstained seminiferous tubule of the rat is observed under a stereomicroscope with transillumination, its light absorption varied with the stages of the cycle (Fig. 18 ). When this technique was coupled with a . microdissection procedure to isolate sections of the tubule corresponding to specific stages of spermatogenesis, biochemical and endocrinological studies of each stage became possible. Readers interested in this technique should refer to either the recent Parvinen review (202, 205) or the original article (206) , for details of the criteria used to identify the . different stages of the rat seminiferous epithelium.
Using this technique, seminiferous tubules from specific stages of the cycle can be pooled and collected in amounts necessary for many biochemical analyses (5-10 cm = 5-10 mg tissue). It should be noted that transillumination is not accurate for identification of all stages of the cycle. Some stages (i.e., -IX, X, XI) are very short in duration and therefore occupy a short length of tubule (from 0.44.8 mm) and must be pooled. Nonetheless, this technique has .
been used by numerous investigators over the past 10 yr and has been instrumental in obtaining the data needed to evaluate the differential regulation of the specific stages of spermatogenesis.
Cyclic Events in Spermatogenesis. The first indications of changes in Sertoli cells which correlated with stages of the seminiferous epithelium were apparent before the transillumination technique. Leblond and Clermont (147) and Lacy (143) using histologic sections of testis showed that Sertoli cell morphology and lipid content varied during the cell cycle. Similarly, it was shown that acid phosphatase activity peaked at Stages VII-VIII (203) . Nonetheless, the majority of information concerning stagespecific changes in physiology has been a direct result of experiments utilizing purified tubule segments from specific stages of spermatogenesis. Table I1 shows the major stage-specific changes which have been documented. This topic has been reviewed by Parvinen (202) and Parvinen et a1 (205) and the reader is referred to these articles for details. A few points will be highlighted here.
First, the Sertoli cell undergoes changes in morphology, lipid content, phagocytotic activity and zyme content during specific stages of spermatogenesis. Thus, the metabolic activities of Sertoli cells appear to be synchronized with the proliferation, maturation, movement and release of germ cells.
Second, FSH stimulation of Sertoli cell function, presumably via an increase in CAMP, varies with the stages of the cycle. There is an age-dependent decline in the ability of FSH to stimulate cAMP accumulation in cultured rat Sertoli cells so that the overall response of adult Sertoli cells is quite low (260) . However, with the use of the transillumination technique, it has been shown that the ability of FSH to stimulate cAMP accumulation is highest in Stages I-IVY while Stages VII and VIII are virtually insensitive to FSH. This is because 1) the significant variation in the binding of FSH to its receptor, 2) the stage-specific variation in ability of FSH to stimulate cAMP production, and 3) the variation in the activity of the cAMP degrading enzyme, phosphodiesterase, during different stages of the cycle. Parvinen et a1 (205) have pointed out that there is a good correlation between FSH responsiveness and the location of the spermatids deep in the Sertoli cell cytoplasm. As the cAMP responsiveness is lost (Stages VII-VIII), there is a concomitant movement of spermatids towards the lumen of the tubule, followed by spermiation at Stage VIII.
Third, there are cyclic changes in the concentration of testosterone in the tubule (highest in Stages VII-IX and lowest in Stages XIII-V). The maximal nuclear androgen receptor concentration is found in Stages IX-I immediately following the highest testosterone concentration. Note that this high androgen receptor level around Stage XIV coincides with meiotic divisions that are dependent upon androgen stimulation. Russell et a1 (221) showed that a low androgen lesion affects cells in Stages XIV and VII, which fits inversely with androgen concentration and receptor number.
Fourth, there are cyclically secreted proteins, i.e., androgen binding protein (Sertoli cell), plasminogen activator (PA) (Sertoli cell and specific forms of spermatocytes), cyclic protein-2 (Sertoli cell), and acid phosphatases (Sertoli cell and specific spermatid forms) (205) . The remarkable complexity. of the system is further shown by the fact that FSH stimulation of PA secretion and androgen binding protein (Stages VII-VIII) from isolated seminiferous tubules is highest in stages which have the lowest number of FSH receptors and lowest' cAMP response.
In addition, stage specificity applies not only directly to the seminiferous tubule, but also to the Leydig cells in the interstitial area. There is a "tubule factor" which reduces Leydig cell testosterone production and is produced in Stages IX-XI. The pro-. duction of this factor correlates with the high tubule concentration of testosterone found in Stage VIII. The Leydig cells are larger and appear closer to the tubule wall in.Stages VII-VIII (15, 16) which suggests a close paracrine regulation of the interstitial and tubule functions, which also varies with the stages of the seminiferous epithelium. 
TOXICOLOGIC PATHOLOGY
It is, therefore, apparent that our understanding of stage-specific events during spermatogenesis, while it has already revolutionized our thinking about the complexity of the regulation and integration of the spermatogenic process, is in its infancy, and there are many more cyclic regulatory processes still to be delineated.
The Sertoli Cell
Overview. The Sertoli cell plays a key role in coordinating a number of aspects of testicular function. As shown in Fig. 19 , the Sertoli cell is in direct contact with both the peritubular and developing germ cells, and in close proximity to the interstitial area. Its functions can be divided into several categories: 1) control of the blood testis bamer (reviewed by Russell (222), Fawcett (80); 2) production of tubule fluid (reviewed by Setchell (23 1)); 3) metabolic regulation of spermatogenesis; 4) paracrine control of spermatogenesis; 5 ) paracrine control of Leydig cell and peritubular cell function; and 6) feedback control of FSH secretion. Many of these aspects of Sertoli cell function have recently been reviewed and will therefore not be covered in detail here (9, 164, 223, 225, 227, 276) .
Our emphasis will be on the "hormonal" control of Sertoli cell function and the role of the Sertoli cell in the paracrine and autocrine control of spermatogenesis. Much of our knowledge in this area has come about because ofthe development of techniques for isolating, purifring and culturing Sertoli cells, the use of the transillumination technique to isolate tubules of specific stages, coculture techniques, i.e., the concomitant culture of 2 different cell types, e.g., Sertoli cells and peritubular cells, and.the examination of the effects of spent media from one cell type on the function of another cell type.
To date, Sertoli cells have been cultured from humans (158) , rats (68, 259, 296) , hamsters (103), bovine (289), porcine (1 23), and monkey (1 94). Sertoli cells can also be cultured in dual environment culture chambers so that secretion into the basal or apical compartment can be measured (35, 124, 125) , or in perfusion chambers where secretions can be continuously monitored (124) .
FSH is still thought to be the main trophic hormone for the Sertoli cell, stimulating both its growth (in immature animals) and differentiated functions. All of the other "hormones" are placed in the category of modulators. FSH acts on the Sertoli cell through specific receptors coupled to the cAMP second messenger system, described previously in this review and reference 9. Sertoli cells, like most cells, also contain an inhibitory pathway of the cAMP system. Adenosine, acetylcholine (hamster) and P-endorphin (/ 3 END) have been shown to act through this inhibitory pathway.
TUBULAR FLUID AND PRODUCT SECRETION

Secretions into
The Ca2+/IP3 second messenger system (see page 412) is present in Sertoli cells, however, its role in modulating Sertoli cell function is unclear: no hormone to date has been shown to activate it (214) . When activated by phorbol esters, the result is an inhibition of the FSH-induced cAMP response, indicating a modulatory role (180) .
Sertoli Cell Regulators. Table I11 shows the staie of our understanding of the endocrine, paracrine,. and autocrine regulation of Sertoli cell function. There are over 20 "hormones" which act on Sertoli cells, presumably via specific receptors, although receptors have not been identified for many of these "hormones." Of the 17 peptide hormone regulators of Sertoli cell function (Table 111) , several are traditional endocrine hormones (e.g., insulin, thyrotropin, glucagon and FSH). The others are either paracrine, autocrine or of unknown origin. Testos-. Thyrotropin ( The peritubular cell has been shown to produce a paracrine regulator of Sertoli cell function; a proteinxalled P-mod-S ( peritubular modifier of Sertoli cell) (248).
In addition, the Sertoli cell produces adenosine, which can act in an autocrine manner to inhibit Sertoli cell response to FSH (62, 183) . Since Sertoli cells produce and respond to prostaglandins, these may also be physiological autocrine regulators (53, 105), as well as possible paracrine regulators of Leydig cells and/or spermatogenesis.
The Sertoli cell responds to several growth factors : (TGF-B, insulin, IGF-I, IGF-11, EGF, and b-FGF) (see Table 111 ). Growth factors usually act in a paracrine fashion. However, TGF-8 (a growth inhibitor) (1 84), b-FGF, IGF-I (somatomedin C) (252), and a growth factor which is epidermal growth factor-like (1 12) have been shown to both be produced by Sertoli cells and to act on Sertoli cells as well as other testicular cells.
The site of origin (i.e., endocrine, paracrine or autocrine) of catecholamines (which activate Sertoli cell 8 receptors) (104, 137) , acetylcholine (muscarinic receptors in hamster Sertoli cells) (6 l), or IGF-I1 (30) are at present unknown.
Sertoli cells also respond to steroids, triiodothyronine (T3) ( 1 99), vitamin D, (1 52,172 ), and retinol (vitamin A) (41, 21 1) (Table IV) . Testosterone, of course, is a major paracrine regulator of Sertoli cell function. In addition, Sertoli cells also have intra- Table IV shows that we really have information about the nature and function of less than 20 secretory products; some of these are classified only in descriptive terms such as "interleukin-like," "LHRH-like," "growth factors,?' "acidic glycoprotein," "testibumin," "proteoglycans" and "cyclic protein 2." Whole new areas of research will be opened up when the functions of the secretions have been defined.
The first Sertoli cell secretory protein to be characterized was androgen binding protein (ABP) (86). Its secretion is stimulated by both FSH and testosterone in v i r a It is secreted bidirectionally, 20% in the blood and 80% in the tubule fluid, which was also the first demonstration of polarization of Sertoli  cell secretion (9,233) . The portion of ABP which is secreted into the tubule is subsequently transported, along with the spermatozoa, to the epididymis. It is apparently taken into the epididymal epithelial cells as it moves through the epididymis, since minimal amounts are detectable in the lumen of the vas deferens. ABP (rat) is a heterodimericglycoprotein with a molecular weight of 85,000; the monomers having TOXICOLOGIC PATHOLOGY
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Homo-Activin B ? 186: 253-264, 1987 (303) . molecular weights of 41,000 and 47,000 are present in a ratio of 3: 1 (9). ABP has now been cloned and sequenced (1 29); however, the physiology lags behind the molecular biology since the mechanism of action of ABP is still unresolved. It does bind testosterone and dihydrotestosterone with high affinity; and therefore has been proposed as a carrier protein. It may provide androgens to the androgenregulated epithelial cells that line the epididymis, as well as play a role in the androgen-sensitive stages of spermatogenesis in the tubule. In this regard, ABP levels in the tubule are cyclic with the highest concentrations occurring in VIII-XI; the stages with the highest testosterone content. It has been proposed that measurement of serum and interstitial fluid ABP might be a valuable marker of Sertoli cell function (99, 234) . . Inhibin is one of the most studied of the Sertoli cell secretory products. There are several recent reviews (153, 302) . While the initial evidence for a water soluble testicular regulator of pituitary function was presented over 50 years ago, it was only a decade ago that Steinberger and Steinberger (26 1) showed that the Sertoli cell was the site of production of a factor which would selectively inhibit FSH release from cultured pituitary cells. This pioneering work led to a resurgence of interest in inhibin, which culminated recently with its purification, cloning and sequencing (153, 302) . Inhibins are glycoproteins of 32 kD, composed of 2 subunits, Two forms of inhibin (A and B) have been isolated which are equipotent. Each inhibin is composed of a common Asubunit (1 8 kD) and a similar but distinct B-subunit (14.7 kD for B, and 14.0 kD for BD) linked by di-sulfide bonds (Fig. 20) . The physiological importance of inhibin has been strengthened by reports which show that the secretion of FSH and production ofinhibin are reciprocally related. For example, there is an inverse relationship between serum FSH and the testicular content of inhibin in cryptorchid rats (6), and FSH has been shown to stimulate inhibin production in cultured Sertoli cells (20, 188) . Also, serum concentrations of inhibin in rats (male and female) vary inversely with serum FSH during development (218, 284) . However, the role of inhibin in the normal adult male rat is unclear, as is the role of FSH! Inhibin is not only produced by Sertoli cells in the testis and granulosa cells in the ovary, but has also been detected in the human placenta, suggesting a role for inhibin during pregnancy (171, 209) . In: hibin mRNA has been detected in the pituitary, adrenal, bone marrow, kidney, spinal cord and brain, suggesting a wider role for inhibins as growthldifferentiation factors (173). Inhibin may also have an intratesticular paracrine role since the a0 heterodimer of inhibin enhanced, and the 00 homodimer suppressed, LH stimulation of Leydig cell testosterone production in vitro (1 14) . This is the first report of a cross-communication between the FSHinhibin feedback system and the LH-testosterone axis.
To further complicate the inhibin story, it must be remembered that inhibin is structurally a member of a class ofglycoproteins, which includes TGF-@, Mullerian inhibiting substance (MIH) and activins. Note that activins result from dimers of the inhibin / 3 chains, while inhibin is a dimer of cy and / 3 chains (303), see Fig. 20 . Activins and TGFP both stimulate FSH release (302). This is another example which highlights our lack of knowledge regarding growth factors.
Sertoli cells, in conjunction with peritubular cells, produce an extracellular matrix, which forms the basal lamina of the tubule. The Sertoli cells produce laminin and Type 1V collagen, while peritubular cells secrete fibronectin and Type I collagen (243) . The close relationship between Sertoli cells and pentubular cells is further exemplified by the fact that Sertoli cells secrete PA and the peritubular cells secrete plasminogen activator-inhibitor. The plasminogen activator-inhibitor (PA-I) released by peritubular cells is postulated to limit the activity of PA secreted by neighboring Sertoli cells. This regulation of PA activity is probably instrumental in the turnover of extracellular matrix and the control of the alterations in the blood testis barrier needed to permit translocation of spermatocytes into the adluminal tubular compartment (141) .
The Sertoli cells also secrete proteins normally found in the serum: transferrin, ceruloplasmin, and acidic glycoprotein (244, 245 ). It appears that the role of testicular transfenin (similar to serum transfemn except for its carbohydrate content) and ceruloplasmin is to transport iron and copper from the serum to the adluminal compartment of the tubule, where they may be important in the spennatogenic process. The demonstration of transferrin receptors on Sertoli cells, spermatocytes and spermatids, and the transport of transferrin-bound iron into Sertoli cells and spermatids is consistent with this hypothesis (277).
. In a more sustentacular role, the Sertoli cell secretes lactate and pyruvate and a keto acids which may be critical for main!aining germ cells. Isolated spermatocytes prefer not to utilize glucose as an energy source. Sertoli cells, however, have a high rate of glycolysis in vitro which results in the production and release of lactate and pyruvate, which could be available as substrates for the developing germ cells (1 30). Similarly, the aminotransferases, which convert branched chain amino acids to a keto acids, are localized in Sertoli cells and not in germ cells. Thus, secreted a keto acids may also be used via the germ cell.specific lactate dehydrogenase-C., isozyme which converts a keto acids t0.a hydroxy acids, thus shuttling reducing equivalents into germ cell mitochondria (83) . Mullerian inhibiting "hormone" (MIH) is synthesized mainly by fetal and perinatal Sertoli cells. It is a natural active regressor (it programs cell death) which in vivo results in the regression of Mullerian ducts in male fetuses (67). Its structure is related to that of TGF-fl and inhibin which are also paracrine growth regulators. An interesting finding on the mechanism of action of MIH is that it stimulates dephosphorylation bf proteins on the plasma membrane of duct cells and thereby antagonizes the effect of epidermal growth factor (292). This shows once again the importance of protein phosphorylationdephosphorylation in cellular regulation.
Several stimulatory growth factors are secreted by the Sertoli cell (1 2, 1 12, 145) . A putative stimulator of germ cell mitosis, termed ,seminiferous growth factor, has been purified and is being examined for its site and mechanism of action. A meiosis stimulating and a meiosis inhibiting factor produced by Sertoli cells appears to be differentially stimulated during the stages of the spermatogenic cycle (202) .
Sertoli cells secrete several products with paracrine action on the Leydig cells. The best characterized of these paracrine regulators is the LHRHlike peptide, which has been shown to have both stimulatory (short-term) and inhibitory (long-term > 24 hr) effects on Leydig cell testosterone secretion (235). Indeed, Leydig cells have LHRH (i.e., GnRH) receptors and the actions of this putative regulator can be mimicked by LHRH. Recently, another factor produced by seminiferous tubules and cultured Sertoli cells, which is not the LHRH-like peptide, has been described (200, 236,288 ). TGF-P and estradiol are also Sertoli cell secretory products, which act to modulate Leydig cell function.
The leukotriene LTB4, which is secreted by Leydig cells, macrophages, and Sertoli cells (264), has been shown to augment LH-induced testosterone production in vitro. Thus, it might serve as an autocrine-and paracrine-regulator of Leydig cell function in vivo. Its possible role in regulation of Sertoli cell function has not been investigated.
The above information concerning Sertoli cell secretions emphasizes the central role of Sertoli cells in modulating testicular function; it also shows the diversity and complexity of these secretions and the need for continued effort in this area to. identify and characterize each of the secretory products. Note also that the secretion of many of these molecules can vary with the stage of the spermatogenic cycle.
Leydig Cells
Overview. The major function of the Leydig cell is the production and secretion of androgens, primanly testosterone, which are necessary for spermatogenesis, as well as the maintenance of reproductive and non-reproductive tissues (bone, muscle, and skin (Fig. 21) ) (237). As described previously, LH provides the most important physiological regulation of testosterone production by the Leydig cells (7 1 , 72, 207, 224, 270 ). This occurs via activation at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from TOXICOLOGIC PATHOLOGY of the cAMP second messenger system. The increased intracellular cAMP then activates protein kinase-A (73), which results in phosphorylation of specific proteins (7), producing an increase in steroid production. A more detailed review of steroid biochemistry can be found elsewhere (140, 207) . Administration of cAMP analogs, such as dibutyryl-CAMP and 8-bromo-cAMPY to Leydig cells also results in an increase in steroid production (163) .
The hypothesis that LH works exclusively through a cAMP mechanism, however, is currently under debate. Several laboratories have reported a discrepancy between the hormone-induced cAMP dose-response curve and steroid production, with as much as a 10to 30-fold increase in testosterone production with no measurable increase in cAMP activity observed (51, 70, 272) In addition, it has been shown that the EDJo for hCG-stimulated testosterone production by Leydig cells is 60 times lower than the EDso of cholera toxin (a direct activator of the cAMP system), while the dose-response curves for cAMP stimulation for the 2 are similar Indeed, recent data suggests that calmodulin and C-kinase are involved in the regulation of Leydig cell steroidogenesis (102, 156) . Like other cells, the C-kinase in purified Leydig cells can be activated by the phorbol ester PMA, resulting in increased testosterone synthesis. Intracellular Ca2+ has also been implicated in LH-dependent steroidogenesis. Trifluoperazine, an inhibitor ofcalmodulin, inhibits the steroidogenic stimulatory effect of LH (102). In addition, when liposomal calmodulin is injected into Leydig cells, testosterone synthesis is increased. Addition of Ca2+ alone is without effect, while addition of Ca2+-saturated calmodulin is greater than that of non-saturated calmodulin. These observations suggest LH may cause a redistribution of calmodulin and this redistribution may effect LH-stimulated androgen synthesis (101). Thus, it appears that although cAMP plays a major role in LH-dependent steroidogenesis, it may not be the only second messenger system active in this process.
Leydig Cell Regulators. Prolactin is a hormone that serves an endocrine role in Leydig cell steroidogenesis. It regulates Leydig cell steroidogenesis by affecting LH receptor number; hyperprolactinemia increases the number of LH receptors and the responsiveness of Leydig cells to LH (237). Prolactin has also been shown to affect Leydig cell aromatase activity in the presence of LH in vitro (201) .
In addition to endocrine regulators of Leydig cell steroidogenesis, several paracrine regulators have been described (Table V) . Due to the fact that several of the testicular cell types are not adjacent, tes- (70) . ticular cell-cell communication is mediated mainly through paracrine factors. With respect to Leydig cell steroidogenesis, it must be remembered that the major regulator of this process is the endocrine hormone LH, and that theparacrine factors most likely are responsible for the modulation of Leydig cell steroidogenesis as they influence the responsiveness of the Leydig cells to LH.
One of the first potential paracrine regulators of Leydig cell steroidogenesis to be recognized was a LHRH-like factor secreted by Sertoli cells (235) . While this factor has not been proven to be LHRH, it is now clear that Leydig cells have specific receptors for LHRH. LHRH and LHRH-like factor can affect Leydig cell steroidogenesis in an inhibitory or stimulatory manner depending upon the length of exposure, the former occurring during a prolonged (3 days or more) period, and the latter during a short exposure time (up to 24 hr) (33, 237). In addition, this factor can alter vascular permeability and tes-.
ticular blood flow further regulating the concentration of testosterone in testicular interstitial fluid. An interesting aspect of this LHRH-like factor is that it appears to not work through a cAMP mechanism but to induce changes in phosphatidylinositol turnover and Ca2+ permeability (52, 179, 265, 270) . Although this factor has not been purified, and its role in steroidogenesis in human and other species' steroidogenesis is controversial, the fact that it is secreted from Sertoli cells and it acts on Leydig cells makes it a good candidate for a paracrine factor involved in the regulation of the local testosterone concentrations necessary for spermatogenesis. Several investigators have described the presence of a factor from Sertoli cell spent media distinct from that of LHRH-like factor, that increases tes- tosterone secretion by Leydig cells in vitro (98, 126, 200, 236, 288) . In general, the factors (they may not be the same) described modulate LH action on Leydig cells, are thermolabile, have molecular weights between 10,000 and 50,000, and are FSH dependent, although 1 investigator described 2 Sertoli cell factors: 1 FSH dependent and 1 non-FSH dependent (126) . It has also been shown that tubular fragments from human testes produce a Leydig cell stimulating factor similar to the factors-listed above (287) . Due to the fact that these factor(s) have not been further characterized or purified, the exact relationship between the factor($ is unknown. Nonetheless, at least 1 factor has been shown to be produced irt vivo in normal rats and the levels in interstitial fluid can vary depending on the intratesticular testosterone level (236). Conversely, a seminiferous tubule factor of probable Sertoli cell origin that inhibits LH-stimulated testosterone secretion by Leydig cells in vitro has also been described (267, 268) . It has been suggested that differential secretion of this inhibiting factor may be an important regulator of the varying testosterone concentrations seen in the different ages of the male rat (268) .
A Sertoli cell factor that increases Leydig cell aro-matase activity in the mature rat has also been recently described (40). This thermolabile, FSH-independent aromatase factor appears to differ from the Sertoli cell factor. which regulates testosterone synthesis because the aromatase-regulating factor requires protein synthesis for its action, whereas the testosterone-regulating factor does not. There has also been a reported aromatase inhibitor that is produced in vitro by isolated seminiferous tubules preferentially at Stages VII-VIII, which are the most androgen-dependent stages of the cycle (28) . The presence of this factor suggests that Sertoli cells are able to maintain high intratesticular concentrations of testosterone by ensuring minimal conversion of testosterone to estrogen by the neighboring Leydig cells.
There have been several reports discussing what at first appears to be an effect of FSH on Leydig cell steroidogenesis. It has been shown that FSH significantly increases testosterone secretion by perfused rabbit testes, and FSH treatment of immature hypophysectomized rats induces Leydig cell hypertrophy, LH receptor number, and increases testosterone secretion in vivo and itt vitro (13, 44, 134, 178,   285 ). This effect of FSH is only evident when Sertoli cells are present, and appears to be specific for FSH since LH alone does not produce the same effect (13, 134) . We now realize that the FSH-dependent increase in Leydig cell steroidogenesis is Sertoli cell mediated through secretions of specific proteins, which increase Leydig cell responsiveness to LH (1 3,  14, 134, 224) . The identity of the proteins secreted by the Sertoli cells in these studies is unknown at this time, but may correspond to the FSH-dependent Sertoli cell factors discussed previously.
Another pathway whereby FSH may indirectly modulate steroidogenesis is through testicular macrophages. Spent media from FSH-stimulated macrophages stimulates testosterone production in a dose-dependent manner when added to Leydig cells in vitro (30 1). Since testicular macrophages represent about 20% of testicular interstitial tissue in adult animals (1 7 9 , the contribution of this factor to Leydig cell steroidogenesis may be significant. Macrophages produce leukotrienes, and leukotrienes stimulate Leydig cell testosterone production, thus, this macrophage factor may be a leukotriene.
Other paracrine factors of testicular origin appear to affect Leydig cell steroidogenesis. A number of studies have reported the presence of the renin-angiotensin system in the male reproductive system. Leydig cells have a specific angiotensin I1 receptor and angiotensin I1 binding activates the Ni subunit of adenylate cyclase, thus inhibiting gonadotropin stimulation of CAMP, resulting in decreased testos-terone production (1 36). Although the significance ofthe renin-angiotensin system in testis is not known, the presence of germinal cell angiotensin-converting enzyme in testicular tubules suggests that angiotensin I1 uses a paracrine regulatory function to negatively modulate hormonal-stimulated Leydig cell steroidogenesis (1 36).
Leydig cells also have receptors for the neurohypophysial hormone arginine vasotocin (AVT) (170) and AVT has been shown to inhibit hCGstimulated testosterone biosynthesis in rat testicular cells (2). Associated with the inhibition of androgen synthesis, an increase in hCG-stimulated pregnenolone and progesterone secretion was also observed (3). Since the concentrations of immunoreactive AVT detected in the testis are higher than those measured in the circulation (19 l), testicular synthesis of AVT is a possibility. Another neurohypophysial peptide, oxytocin, was also shown to increase testosterone accumulation under basal conditions Catecholamines have been shown to have an effect on testicular testosterone production. It has been known for several years that stress and systemically adm'inistered catecholamines inhibited testosterone secretion iit vivo (59, 256) , whereas catecholamine treatment of Leydig cells in vitro has a stimulatory action (5) . This stimulation occurs through a CAMP mechanism, mediated through specific P-adrenergic receptors present on Leydig cells. There is no evidence that catecholamines have a direct inhibitory effect on Leydig cells in vitro, and the possibility exists that an indirect inhibition occurs through Sertoli cells, which have been shown to havep receptors in vitro (104, 137).
Recently, several new factors have been shown to affect Leydig cell steroidogenesis. Corticotropin-releasing factor (CRF) is most likely produced in the testis, and the Leydig cell may be the target cell type for its action (304). Leydig cell steroidogenesis can also be inhibited in vitro by. interferons (196) and serotonin (36) and stimulated by benzodiazepines (2 15) . Leydig cells also possess specific atrial natriuretic factor (ANF) receptors, and rat atriopeptin type I1 (rAP-11) increases testosterone pro'duction by isolated adult rat Leydig cells (85).
Insulin and specific growth factors can also regulate Leydig cell steroidogenesis. Leydig cells have specific receptors for both insulin and IGF-I and these have been shown to increase basal and hCGstimulated testosterone production (1 57). Diabetic animals have been reported to have reductions in . 
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androgen production, Leydig cell number, and LH receptors, which can be reversed by insulin administration (43, 57) , indicating that Leydig cells are a target for insulin and IGF-I. Some growth factors inhibit Leydig cell function. TGF-p has been shown to decrease testosterone synthesis in cultured adult rat Leydig cells in vitro, whereas TGF-a had no effect in the same culture system (155). It appears that EGF can either stimulate or inhibit Leydig cell steroidogenesis, depending on the length of time the cells have been in culture (1 13, 297) . The relevance of EGF to Leydig cell steroidogenesis in vivo must be further explored.
Leydig Cell Secretory Prodiicts. Leydig cells, in addition to being responsive to paracrine regulation, also secrete specific proteins, which are paracrine and autocrine regulators ( Table V) . As stated earlier, the most important Leydig cell product is testosterone. Its specific role in spermatogenesis is unknown to date, but testosterone has specific paracrine actions on Sertoli cells iiz vitro; it stimulates ABP secretion (99), and RNA polymerase activity Testosterone is also an autocrine regulator of its own secretion. When a physiologically relevant concentration of testosterone is infused into a rat testicular artery in vitro, LH-stimulated testosterone secretion is inhibited (60). Estrogen secretion is another autocrine mechanism for control of Leydig cell testosterone production. Leydig cells use aromatase to convert androgens to estrogens; a process sti.mulated by LH. Estrogens inhibit 2 important enzymes in the androgen synthetic pathway (1 7-a- hydroxylase and 17-20 lyase). This desensitization only occurs in adult animals, since fetal and im-mature animals have little aromatase activity, and low levels of estrogen receptors (279) .
Recent evidence indicates that some of the communication between Leydig cells and seminiferous tubules occurs via opioid peptides. POMC-derived peptides were originally described in the anterior and intermediate pituitary. Testicular POMC-derived peptides, specifically ACTH, a-MSH and /3 END are produced by Leydig cells (1 0,280) . Recent in vitro studies determined that LH stimulates / 3 END production (29,79). As described in the Sertoli cell section, / 3 END inhibits FSH-induced cAMP accumulation, Sertoli cell proliferation, protein secretion, and basal and FSH-stimulated ABP production in young rats, possibly inhibiting Sertoli cell growth and secretion during early testicular development (78) . /3 END had no effect on adult Sertoli cell ABP secretion (91) . In contrast, other POMC peptides such as ACTH and MSH-like peptides stimulate Sertoli cell cAMP (1 65, 185) . In addition to this paracrine role, POMC-derived peptides may also have an autocrine function. The effect of POMC peptides on testosterone production by the Leydig cell has been studied by several investigators, with varying results. In several studies, it was shown that @ END antagonists inhibited Leydig cell testosterone secretion (29, 9 1) . In other reports, /3 END itself inhibited testosterone secretion (1 lo), or had no effect (79, 238) . Thus, it appears that POMC-derived peptides act as paracrine regulators of Sertoli cells, but this action as an autocrine regulator of testosterone production is less clear.
Oxytocin is a secretory product of Leydig cells which acts on the myoid cells of the tubule to bring about their contraction. These contractions are thought to aid the transport of the shed sperm to the rete testis (237) . It als6 ,may act in an autocrine manner on the Leydig cells, since there is some indication that Leydig cells may have oxytocin receptors (271) .
Two main points summarize this section: 1) the Leydig cell function is finely regulated by the integration of multiple receptors coupled to multiple second messengers; and 2) testosterone can no longer be considered as the product of the Leydig cells, since they produce, other autocrine and paracrine products, which help optimize testicular function.
Peritiibtilar Cells
Overview. Peritubular cells, together with collagen and other extracellular matrix components in the boundary tissue, form the tubular wall; At one time, it was felt that the sole function of peritubular cells was their ability to contract. It is now evident that peritubular and Sertoli cells interact in several ways to maintain proper tubular structure and regulate spermatogenesis. . (228, 248) . In addition, as was discussed in the previous section, oxytocin, secreted by Leydig cells, acts upon the pentubular cells to cause their contraction, which propels the released sperm toward the rete testis (Table VI) .
Perittibtilar Cell Regulators. Peritubular cells have androgen receptors and respond to androgens by secretion of proteins
Perittibtilar Cell Secretory Prodticts. Peritubular cells and Sertoli cells synthesize different extracellular matrix proteins. Therefore, cooperation between the 2 cell types is necessary for basal lamina formation and formation of a tubule-like architecture (282, 283) . Peritubular cells secrete fibronectin and Type I and IV collagen while Sertoli cells secrete Type IV collagen and laminin (87) . The cooperation between the 2 cell types is further demonstrated by the ability of peritubular cell-Sertoli cell cocultures to survive for months, while either cell type alone cannot survive more than a few weeks (1 18, 283) .
Paracrine communication between. peritubular and Sertoli cells has also been demonstrated in that media from peritubular cell cultures stimulates, in a dose-dependent manner, secretion of ABP, transfemn, and a lactalbumin-like protein by cultured Sertoli cells (1 1 1, 1 17, 249) . Factor@) referred to as "P-mod-S" protein secreted by peritubular cells that modulates Sertoli cells has been isolated from peritubular cell cultures (248) . This factor(s) is trypsin and heat sensitive, with an apparent molecular weight of 50,000. Secretion of this component is stimulated by androgens, which is consistent -with the presence of androgen receptors in peritubular cells. P-mod4 does not appear to work through a cAMP mechanism (1 17). It is suggested that Leydig cell androgens stimulate P-mod4 secretion, which then modulates specific Sertoli cell functions (250) . This type of paracrine communication between the 3 cell types exemplifies the complex interactions necessary for proper testis regulation.
Peritubular cells also secrete an inhibitor of plasminogen activator activity (PA-I) (107). PA-I from the peritubular cells may play a regulatory role in modulation of the stage specific activity of the proteases secreted by the neighboring Sertoli cells.
.
Germ Cells
Germ cells and Sertoli cells are in contact in the seminiferous tubule (see Fig. 19 ). There is extensive electron microscopic evidence that the Sertoli cells have gap junctions with "their" germ cells (168) . Additionally, the complex ultrastructural changes that occur in the regions of the Sertoli cell close to the germ cells, during spermatogenesis, strongly sug-TOXICOLOGIC PATHOLOGY gest that the Sertoli cells secrete compounds that are directly necessary for germ cell survival (223) . Two Sertoli cell secretions that are obligatory for germ cell development are lactate and pyruvate. These substances probably act as an energy source for germ cells, which prefer not to utilize glucose (1 30 ). It has also been suggested that because Sertoli cells secrete transferrin and germ cells have specific binding sites for this transport protein, it may contribute more to germ cell development than just an iron-transport function (277) . In addition, Sertoli cells have also been shown to secrete a mitogenic substance termed seminiferous growth factor which may play a role in spermatogonial proliferation, mitosis, or promotion of testicular development (8 1) (Table VI) .
Sertoli cells appear to regulate germ cell maturation at the level of cell division, in part, by the secretion of 2 proteins-meiosis-initiation and meiosis-inhibiting factors. It appears that secretion of the meiosis-initiating factor is greatest at Stages VII and VIII, while meiosis-inhibiting factor shows no cyclic variation in secretion. It has been suggested that under normal conditions, meiosis is prevented by the inhibiting factor, and secretion of the initiating factor stimulates meiosis at the proper stages (202, 205, 237) . EGF has also been implicated in the stimulation of meiosis (281). Removal of the submandibular gland (which releases large amounts of EGF systemically) decreased the number of mature sperm and spermatids, whereas the number of spermatocytes was increased.
Using germ-Sertoli cell coculture, it has been determined that FSH stimulation of Sertoli cells results in increased synthesis of germ cell RNA and DNA. The identification of this proposed stimulating factor is unknown (2 17) .
It also appears that germ cells are able to regulate Sertoli cells. It has been shown in vitro and in vivo that when germ cells are'destroyed, a decrease in Sertoli cell-specific functions occurs (88, 127) . FSHdependent ABP secretion by Sertoli cells is greatly increased when Sertoli cells are cultured in the presence of germ cells (89, 148, 149) . This stimulation occurred when pachytene spermatocytes were added to Sertoli cells in vitro and adhered to the Sertoli cells, and the effect was specific for germ cells. Although the mechanism for this enhancement is unknown, germ cells and Sertoli cells form gap junctions in vitro (89, 305) as they do in vivo. In addition, germ cells increase phosphorylation of two specific Sertoli cell proteins (1 19) . The identity of these proteins has yet to be determined. Thus, germ cells may be directly involved in the regulation of Sertoli cell function through several mechanisms.
Germ cells cannot be cultured for long periods without the presence of Sertoli cells, indicating an absolute dependence on Sertoli cells. It appears that germ cells must have Sertoli cells for survival, although the reverse is not true.
Evidence also exists that germ cells may communicate with Leydig cells. Leydig cells that are surrounded by tubules in Stages VII and VIII are larger than those in other stages or those next to perivascular tissue (1 6). Furthermore, upon damage to the germ cells by cryptorchidism, all the Leydig cells decreased to the smaller size. This variation in Leydig cell size appears to be a relevant phenomenon, due to the fact that Stages VII and VIII are the most androgen-dependent stages of the tubule. These data indicate the presence of another paracrine fac-. tor that is secreted in a stage-specific manner.
The identity of most germ cell paracrine factors is not known, but recently the presence of POMCderived and proenkephalin peptides have been described in germ cells' (76, 138) . Since POMC derived peptides regulate Sertoli cell and Leydig cell function, the possibility exists that these substances could have a similar action on germ cells. In summary, Fig. 22 emphasizes the complex interaction among the various compartments of the testes, which are just beginning to be understood. It appears that through endocrine, paracrine, and autocrine mechanisms, the function of each cell type is modulated to integrate its activity with that ofthe other cells. This complex interrelationship must be taken into account when the toxicology of the reproductive system is assessed. 
INTRODUCTION TO MALE REPRODUCTIVE TOXICOLOGY
Over the past 10 yr, there has been a substantial interest in both scientific and private communities, with regard to the potential of environmental, industrial, and therapeutic chemicals to interfere with male reproductive functions. There are several recent reviews and monographs which delineate the nature of the over 100 chemicals, which have been shown to be toxic to the male reproductive system inrodents(l7; 65, 69, 146, 166, 210, 229, 274, 293) .
The previous sections reviewed the components of the male reproductive system and emphasized that the normal functioning of this system is dependent upon complex interrelationships between several different compartments and processes, each of which is a possible site of action for toxic chemicals. However, our knowledge of the site and mechanism ofaction ofmost toxicants is not yet as refined as our understanding of the physiology. Nonetheless, toxicants are known which appear to specifically affect each of the general compartments of the reproductive system (Table VII) . In order to help in our understanding of the sites of action of reproductive toxicants, they can be broadly classified into 2 groups; direct and indirect acting. Fig. 23 shows the general sites of action of reproductive toxicants. From a physiologist's point of view, those that affect spermatogenesis, epididymis, seminal vesicles, or prostate are termed direct acting, while those that affect the CNS, pituitary, liver, nutrition, testicular vasculature, or pineal are termed indirect acting. While it sounds confusing, the direct and indirect acting toxicants can be further divided. From the xenobiotic metabolism perspective, "direct acting" compounds are those which are themselves the active agent while those which require metabolic activation are termed "indirect acting." Using both definitions, the following 2 reports will detail some approaches to elucidating the sites and mechanism of action of reproductive toxicants. 
